Lasalocid is an ionophore used as a growth promotant feed additive in cattle and as a coccidiostat in cattle, sheep, and poultry. 1, 10 Lasalocid toxicosis has been reported in feeder calves following feed mixing errors 4 and in neonatal calves after administration of lasalocid. 9 In the absence of an approved treatment for cryptosporidiosis in neonatal calves, the off-label use of lasalocid for this purpose has been attempted in the field using several dosage forms. In this report, we describe 2 cases of lasalocid toxicosis resulting from use of a commercially available liquid coccidiostat/antidiarrheal compound containing lasalocid. In an effort to more accurately characterize postmortem lesions and clinical signs and to rule out the effects of the polypharmacy reported in the field cases, 2 newborn calves were dosed experimentally with the commercial coccidiostat used in the field cases.
Two cases of bovine neonatal death loss were submitted to the Iowa State University Veterinary Diagnostic Laboratory. In the first case, 3 calves were submitted for postmortem examination. A liquid oral coccidiostat had been used at 4 times the label dose as a preventative for cryptosporidiosis, providing 200 mg of lasalocid per dose given once daily by depositing the liquid with a syringe in the posterior oral cavity beginning within 12 hours of birth. In addition, the calves were given injections of flunixin meglumine, gentamicin, and Clostridium perfringens types C and D antitoxin and oral doses of E. coli K99 monoclonal antibody and enrofloxacin. Calves were found dead or in lateral recumbency with opisthotonos within 12-24 hours after adminis-tration of the drug. Necropsies were performed, and tissues were collected in formalin and routinely processed for light microscopic examination. Bacteriologic cultures were made from lung, intestinal sections, liver, spleen, and brain. Spleen, lymph node, and colon were used for direct fluorescent antibody examination, feces were used for enzymelinked immunosorbent assay and lung, spleen, and lymph nodes were used for virus isolation.
In the second case, a 36-hour-old calf developed clinical signs of recumbency, dyspnea, and ataxia and died after receiving since birth 100 mg lasalocid in each twice-daily feeding of milk replacer (total of 3 doses). Fresh and formalin-fixed specimens of brain, cardiac muscle, lung, spleen, kidney, and rumen were submitted for histopathologic examination and bacteriologic and virologic tests.
In the first case, postmortem examination revealed severe pulmonary congestion and moderate interlobular edema. Two of the calves had milk curd in the abomasum. No other gross changes were observed. On histopathologic examination the lungs were diffusely congested and had abundant proteinaceous fluid and fibrin in the alveoli. In addition, 1 calf that had survived for 24 hours had focal areas of purulent bronchopneumonia. No significant histopathologic changes were observed in the brain, thyroid, thymus, cardiac muscle, skeletal muscle, small intestine, large intestine, liver, kidney, or adrenal gland. No evidence of cryptosporidial infection was observed. Bacterial cultures of the tissues did not result in the isolation of any pathogens. Direct fluorescent antibody examination and virus isolation procedures did not demonstrate the presence of rotavirus, coronavirus, or bovine viral diarrhea virus.
Postmortem lesions seen in the second case were pulmo- nary and meningeal congestion. Histologic examination of the pulmonary parenchyma revealed widespread areas that contained proteinaceous fluid, fibrin, and leukocytes in the alveoli. Scattered hemorrhages were noted in the alveoli and interlobular septa. The interlobular septa were widened with proteinaceous fluid. The airways contained small amounts of proteinaceous fluid and few leukocytes. No significant histopathologic changes were observed in the cardiac muscle, spleen, kidney, or rumen. Analysis of the stomach contents revealed traces of lasalocid. No evidence of cryptosporidial infection was observed. Bacterial cultures did not result in the isolation of any pathogens.
Based on the clinical presentation and history of lasalocid therapy, a tentative diagnosis of lasalocid toxicosis was reached in both cases. Following withdrawal of the product, death losses ceased.
Two newborn calves were dosed experimentally with the commercial coccidiostat used in the field cases at 4 times the label dose, providing 200 mg lasalocid/dose or approximately 5 mg/kg body weight. The product was administered by depositing the liquid with a syringe in the posterior oral cavity once daily, with the first dose given at approximately 12 hours of age. No other drugs or injections were administered. Predosing and multiple postdosing blood samples were drawn by jugular venipuncture at approximately 1-hour intervals and analyzed for creatine kinase (CK), aspartate aminotransferase (AST), albumin, total protein, glucose, creatinine, blood urea nitrogen (BUN), magnesium, phosphorus, calcium, total CO 2 content, chloride, potassium, sodium, and lasalocid concentration. In 1 calf, a continuous electrocardiogram (EKG) recording was obtained. b Calves were maintained on milk replacer until death occurred. Necropsies were performed and samples of brain, lung, thyroid, thymus, heart, liver, spleen, kidney, adrenal gland, rumen, reticulum, omasum, abomasum, small and large intestine, and skeletal muscle were fixed in 10% buffered formalin for examination by light microscopy. Liver tissue was evaluated for selenium concentration to establish that these levels were adequate.
The calves developed respiratory distress and incoordination and were prostrate within 12 hours of receiving the first dose. Muscle weakness was especially apparent in the pelvic limbs, as indicated by a reluctance to stand and an inability to support weight, causing a bilateral ''knuckling over'' of the fetlocks. The calves became laterally recumbent with opisthotonos. Both calves died approximately 36 hours after the first dose was administered. An EKG record revealed tachycardia in excess of 120 beats/minute (BPM) beginning approximately 90 minutes after dosing and persisting for 30 hours and 54 minutes; average heart rate for the duration of the test was 151 BPM; the highest rates were 209 BPM for 36 minutes beginning 10 hours 15 minutes after the first dose and 224 BPM for 21 minutes beginning 9 hours 21 minutes after the second dose. Premature ventricular contractions occurred at a rate of approximately 6/hour and were not considered significant.
Serum and blood chemistry values were unremarkable with the exception of AST and CK. AST levels increased above reference ranges of 55-125 IU/liter within 22 hours after the first dose and gradually increased to a high of 292 IU/liter. CK levels exceeded the reference range of 1-350 IU/liter within 1.5 hours after the first dose and gradually increased to 1,505 IU/liter by 29 hours; within the next 3 hours they reached a high of 9,570 IU/liter (Fig. 1) . Lasalocid levels increased rapidly to 867 ppb by 6 hours follow- ing first dose administration. Levels again increased after the second dose, reaching a high level of 4.47 ppm by 8 hours postdosing. Analysis of liver tissue revealed 530 ppb selenium; this value is considered within normal parameters.
Gross lesions included pulmonary congestion and mild hyperemia of the abomasum. Marked edema and ecchymotic hemorrhages were noted in the gluteal muscles.
Microscopic lesions included mild, multifocal myocardial necrosis and mild, fibrinous pulmonary effusion. There was necrosis of the rumen papillae characterized by karyorrhexis and ballooning degeneration of the epithelial cells, formation of intraepithelial microvesicles containing neutrophils, and necrosis of the lamina propria involving from one-third to one-half of the distal papillae (Fig. 2) . A zone of neutrophils and karyorrhectic debris marked the border of the necrotic area. Mild, multifocal areas of ballooning degeneration and necrosis were noted in the mucosa of the omasal folds. Severe coagulative necrosis of skeletal muscle fibers with interstitial edema, mild to moderate hemorrhage, and mild neutrophil infiltrates were observed in the gluteal muscles; lesser degrees of necrosis, edema, and inflammation were observed in other skeletal muscles ( Fig. 3) o. There was mild swelling of the vascular endothelial cells in the brain. No lesions were observed in the other tissues.
Lasalocid has been reported to cause toxic effects when administered to neonatal calves. 9, 12 Death loss in neonatal calves was associated with the use of a dry form of lasalocid in gelatin capsules. 9 Calves were given 150 mg of lasalocid once daily, approximately 3 mg/kg, as a treatment for cryptosporidiosis. Clinical signs described included depression, weakness, central nervous system disturbance, recumbency, enteritis, and death. At necropsy, raised plaque-like lesions were observed in the rumen. Histopathologic changes were not reported. In an experimental study on lasalocid as a treatment for cryptosporidiosis, 6 of 10 calves dosed at 8 mg/kg developed dyspnea and died. 12 Gross lesions at necropsy were pulmonary, mediastinal, mesenteric, and subcutaneous edema and serous effusion into the pleural, pericardial, and peritoneal cavities. Histopathologic changes were not described.
In the present investigation, both field case calves and experimental calves received approximately 5 mg/kg and had similar clinical signs: initial dyspnea and ataxia followed by recumbency with terminal opisthotonos. In the experimental calves, the recumbency with dyspnea and tachycardia developed within 12 hours of treatment. Gross lesions observed at necropsy were limited to pulmonary edema and edema and ecchymotic hemorrhages in the gluteal muscles.
In the field cases, microscopic lesions were limited to the lungs. Rumen tissue was not examined microscopically in the first field case and was unremarkable in the second field case, in which the lasalocid was mixed with milk replacer and may have bypassed the rumen.
In the experimental calves, in addition to pulmonary edema, microscopic lesions of rumen papillary necrosis and extensive focal skeletal muscle necrosis were also observed. No gross lesions were observed in the rumen. The dry form of the drug used in the previous case may have caused more intense local effects than did the liquid preparation used in these calves. Severe skeletal muscle necrosis, reflected in the elevated CPK levels, was observed in the experimental calves. Gross skeletal muscle lesions were not observed in the field cases, and skeletal muscle was examined histopathologically only in the first field case. These lesions may not have had adequate time to develop in the field cases in which death occurred within the first day following exposure. In addition, the focal nature of the lesions increases the likelihood of failure to sample an affected area.
Ionophores form complexes with cations and mediate their transport across the cell membrane in response to diffusion gradients. 3 Depletion of cellular ATP occurs as ATP-dependent pumps attempt to compensate for the influx of ions. Failure of ion pumps results in elevated intracellular sodium and calcium concentrations, cellular swelling, metabolic disruption, and necrosis. 3 Both skeletal and cardiac muscle are susceptible to these changes. In the experimental calves, the finding of skeletal muscle necrosis is consistent with reports of ionophore toxicosis in sheep, swine, and horses. 5, 7, 11, 13 The lack of myocardial lesions in the experimental calves may have been due to the short time period from initial dosing to death.
Lasalocid toxicosis also has been described in older feeder calves but at doses significantly higher than those associated with toxicosis in neonates. 4, 6 In an experimental study, single doses of 10 mg/kg had no effect, whereas doses of 50 mg/kg or higher resulted in tachycardia, muscle tremors, diarrhea, and death in 5 of 6 animals treated. 5 Gross lesions were pleural effusion, myocardial petechiae, and cardiac dilatation. Toxicosis associated with a feed mixing error also has been reported; in that case, feed samples contained 1,010-1,700 ppm lasalocid, 50 times the recommended concentration of 33 ppm, which would have been expected to deliver the recommended dosage of 1 mg/kg/day. 4 Lesions at necropsy were myocardial hemorrhage and pleural effusion. The most consistently reported histopathologic change in intoxicated feeder calves has been myocardial necrosis. 4, 6, 14 Rumen and skeletal muscle lesions were not reported.
Whether the higher sensitivity of neonates is due to differences in absorption or metabolism is unknown. Calves are capable of rather indiscriminate uptake of macromolecules up to about 48 hours of age, and absorption of any agent may be enhanced during this period. 2 Experimental trials with lasalocid as a treatment for cryptosporidiosis in calves Ͼ7 days of age produced no toxic effects at daily doses of Յ15 mg/kg. 8, 10, 15 This finding suggests that lasalocid is significantly more toxic for calves Ͻ7 days of age. The toxicity of lasalocid for neonates may be enhanced by delivery of the product directly into the rumen by bolus or stomach tube; however, the significance of this observation is unclear. 9 Administration by mixing with milk replacer delivers the product into the abomasum through the mechanism of esophageal groove closure stimulated by the nursing reflex. Although the local effects on the rumen would undoubtedly be avoided when bypassing the rumen, the systemic effects may not be altered; in the second field case, the product was administered in milk, and the toxic effects were sufficient to cause death.
Chemical analysis for lasalocid residues in blood, milk, liver, skin, and fat has been described; 16 however, no parameters specifying toxic levels of lasalocid in these tissues have been documented. The demonstration of lasalocid in tissues may be significant in cases of accidental administration; however, until quantitative data are generated identifying toxic levels, demonstration of lasalocid in tissues in cases of known administration is of questionable value.
Sources and manufacturers
a. Calf-Pro, Animal Technology, Bozman, MD. b. SpaceLabs, Redmond, WA. nation were selected from experimentally infected animals and from diagnostic cases submitted to the University of Nebraska-Lincoln Veterinary Diagnostic Center. Serial 4m sections from each block of formalin-fixed, paraffin-embedded tissues were mounted on slides a and allowed to dry overnight. Sections were deparaffinized and then subjected to either HMAR or protease digestion. The HMAR slides were placed in a Coplin jar containing 0.01 M citric acid monohydrate, pH 6.0. The Coplin jar was loosely covered with aluminum foil, and the slides were autoclaved for 10 minutes at 120 C and 20 psi. The autoclaved slides were rinsed by dipping once in distilled water and were loaded onto an automated immunostainer. b Slides for protease treatment were placed in the immunostainer, and the immunostaining procedure for the antigen in question was started. The stainer applied 0.05% (w/v) protease XIV c to each protease-treated slide. Protease was replaced by Tris-buffered saline (TBS, pH 7.6) and applied to all HMAR slides during this processing step. The incubation period for protease was variable depending on the antigen and tissue but was between 5 and 10 minutes. All slides were then washed 3 times for 3 minutes each with TBS. The protease-treated slides and the HMAR slides were then processed identically. A commercially available avidin-biotin complex alkaline phosphatase kit d and substrate kit e were used according to the manufacturers' instructions. Primary antibodies used for each antigen are indicated in Table 1 . A serial section stained with an irrelevant antibody was included for each antigen as a control for specificity of staining. All slides were counterstained with hematoxylin.
HMAR resulted in superior staining for BRSV, N. caninum, M. hyopneumoniae, and group A rotavirus, as compared with the protease-treated slides. The most dramatic effect of HMAR was observed for these antigens. Specific staining was distinctly present in HMAR slides but there was no staining of the protease-treated slides for these antigens. As an example, staining for group A rotavirus with monoclonal antibody (MAb) 9-10 (supplied by one of us [RAH]) was readily evident in HMAR slides; protease-treated sections
